Serpil Oğuz Mızrakçı

Department of Infectious Disease, Lara Anatolia Private Hospital, Antalya, Türkiye

Keywords: Acinetobacter baumannii, carbapenem resistance, fosfomycin.


Multi-drug resistant (MDR) Acinetobacter baumannii is now a major pathogen responsible for morbidity and mortality in intensive care units. Fosfomycin has been used as a "salvage" therapy in these cases. Resistance to colistin, which was frequently used in the treatment of Acinetobacter baumannii infections in previous years, has pushed the use of fosfomycin to the forefront of research. The purpose of this review was to draw attention to the potential risk of MDR Acinetobacter infections in Türkiye.

Cite this article as: Mızrakçı SO. The use of fosfomycin in the treatment of carbapenem-resistant Acinetobacter infections. D J Med Sci 2022;8(2):90-95.

Data Sharing Statement:
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflict of Interest

The authors declared no conflicts of interest with respect to the authorship and/ or publication of this article.

Financial Disclosure

The authors received no financial support for the research and/or authorship of this article.